BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
BTIG Downgrades Magenta Therapeutics to Neutral
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
Related Posts
EF Hutton Maintains Buy on Exelixis, Maintains $24 Price Target
EF Hutton analyst Michael King maintains Exelixis (NASDAQ:EXEL) with a Buy and maintains $24 price target.
Amdocs and Microsoft Collaborated Over Intelligent Customer Engagement Platform
Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, and Microsoft Corp. today announced a new Customer Engagement Platform. The platform will empower service
Perion Network Stock Gets Boost From Q2 Beat, Guidance Lift
Perion Network Ltd (NASDAQ: PERI) reported second-quarter FY23 revenue growth of 22% year-on-year to $178.5 million, beating the